Skip to content

Role of radiation therapy in advanced stage thyroid cancer

Phase II randomized Controlled trial of postoperative Intensity modulated Radiotherapy (IMRT) in locally Advanced Thyroid Cancers. - THYRO-RT

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/12/007585
Enrollment
72
Registered
2016-12-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- PATEINTS WITH LOCALLY ADVANCED NON METASTATIC THYROID CANCER IN GOOD GENERAL CONDITION

Interventions

Intervention1: Radiation therapy: patients will receive surgery followed by radioiodine therapy followed by external beam radiation therapy (IMRT) THE TOTAL DURATION OF THERAPY- 6-8 WEEKS Control Inte

Sponsors

Tata Memorial Hospital Intramural fundin
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A) All patients of thyroid cancer (papillary/follicular/poorly differentiated) who have undergone total/completion thyroidectomy at our institute and having at least two of the following features (listed below) intra-operatively and/or on histopathology 1. Gross extrathyroidal spread into soft tissues of the neck, trachea, esophagus, recurrent laryngeal nerve (constituting stage T4a) 2. R1/ shave resections (minimal residual disease) 3. R2 resections (gross residual disease) 4. Multiple lymph nodes positive( >2) with perinodal extension at level VI B) Normal baseline haematological and biochemical parameters

Exclusion criteria

Exclusion criteria: 1. Anaplastic or medullary thyroid cancer 2. Previous history of radiation 3. Pregnancy 4. 5. Patient unwilling to participate in the study

Design outcomes

Primary

MeasureTime frame
â?¢ To assess the impact of adjuvant RT on loco-regional control in patients with locally advanced differentiated thyroid cancers who have undergone surgery with radioiodine therapyTimepoint: â?¢ Assessment for locoregional recurrence will be done at every follow up upto five years after completion of treatment.

Secondary

MeasureTime frame
â?¢ To assess toxicity (early and late at 2 years) of adjuvant RT in these patientsTimepoint: at 2 years

Countries

India

Contacts

Public ContactDR GOURI PANTVAIDYA

TATA MEMORIAL HOSPITAL

docgouri@gmail.com919833971155

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026